- Home
- CAPR vs AACB Comparison
CAPR vs AACB Comparison
Compare CAPR & AACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- AACB
- Stock Information
- Founded
- CAPR 2005
- AACB 2024
- Country
- CAPR United States
- AACB United States
- Employees
- CAPR N/A
- AACB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- AACB
- Sector
- CAPR Health Care
- AACB
- Exchange
- CAPR Nasdaq
- AACB Nasdaq
- Market Cap
- CAPR 324.6M
- AACB 298.1M
- IPO Year
- CAPR N/A
- AACB 2025
- Fundamental
- Price
- CAPR $6.28
- AACB $10.13
- Analyst Decision
- CAPR Strong Buy
- AACB
- Analyst Count
- CAPR 8
- AACB 0
- Target Price
- CAPR $24.75
- AACB N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- AACB 138.0
- Earning Date
- CAPR 08-11-2025
- AACB 01-01-0001
- Dividend Yield
- CAPR N/A
- AACB N/A
- EPS Growth
- CAPR N/A
- AACB N/A
- EPS
- CAPR N/A
- AACB N/A
- Revenue
- CAPR $13,392,150.00
- AACB N/A
- Revenue This Year
- CAPR N/A
- AACB N/A
- Revenue Next Year
- CAPR $6,061.53
- AACB N/A
- P/E Ratio
- CAPR N/A
- AACB N/A
- Revenue Growth
- CAPR N/A
- AACB N/A
- 52 Week Low
- CAPR $3.98
- AACB $10.00
- 52 Week High
- CAPR $23.40
- AACB $11.35
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- AACB N/A
- Support Level
- CAPR $6.17
- AACB N/A
- Resistance Level
- CAPR $7.30
- AACB N/A
- Average True Range (ATR)
- CAPR 0.43
- AACB 0.00
- MACD
- CAPR -0.11
- AACB 0.00
- Stochastic Oscillator
- CAPR 4.53
- AACB 0.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.